Difference between revisions of "Docosatetraenoyl ethanolamide"
From Self-sufficiency
m (Citations: [Pu173] added: pmid, issue. You can use this bot yourself! Report bugs here.) |
m (1 revision) |
(No difference)
| |
Latest revision as of 21:09, 21 September 2010
| Docosatetraenoyl ethanolamide | |
|---|---|
| File:Docosatetraenoyl ethanolamide.png | |
| (7Z,10Z,13Z,16Z)-N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide | |
| Other names DEA | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 150314-35-5 |
| PubChem | 5282273 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C24H41NO2 |
| Molar mass | 375.59 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Docosatetraenoyl ethanolamide (DEA) is an endogenous chemical that has been shown to act on the cannabinoid (CB1) receptor.[1] DEA is similar in structure to anandamide (AEA, a recognized endogenous ligand for the CB1 receptor), containing docosatetraenoic acid in place of arachidonic acid. While DEA has been shown to bind to the CB1 receptor with similar potency and efficacy as AEA, its role as a cannabinergic neurotransmitter is not well understood.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ Hanus, L., Gopher, A., Almog, S.; et al. (1993). "Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor". J Med Chem. 36 (20): 3032–3034. doi:10.1021/jm00072a026. PMID 8411021.
